

## Addendum

Following the circulation of the appeal letter a small number of errors were identified. These errors do not affect the reasoning of the letter, which is published on the Institute's website in its original form. However, for completeness, the appropriate wording is set out below, with corrected errors underlined.

Paragraph	Correction
15	<p>The third bullet point should read:</p> <ul style="list-style-type: none"><li>• Tacrolimus is a calcineurin inhibitor. The Appraisal Committee considered preparations of immediate-release tacrolimus and of prolonged-release tacrolimus. Brands of immediate-release tacrolimus with marketing authorisations in the United Kingdom include Adoport (Sandoz), Capexion (Mylan), Perixis (Accord Healthcare), Tacni (Teva) and Vivadex (Dexcel Pharma).</li></ul> <p>Astellas Pharma Ltd markets immediate-release tacrolimus as <u>Prograf</u> and <u>Modigraf</u> and prolonged-release tacrolimus as <u>Advagraf</u>.</p>
16	<p>Ms Fiona Loud represented the <u>British Kidney Patient Association</u></p>
53	<p>The second paragraph should read:</p> <p>As outlined above, the Appeal Panel noted the Committee's position that the recommendations in the Final Appraisal Document only applied to first-line treatment. The Appeal Panel therefore did not consider whether it was reasonable to reach firm conclusions regarding the value of <u>prolonged-release tacrolimus</u> for second-line treatment.</p>